{"result": {"id": "5deb7066-b178-474c-b168-d40c24833d1a", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "{\n    \"title\": \"ACCORD STUDY GROUP and Cardiovascular Research Community\",\n    \"summary\": \"The community is centered around the ACCORD STUDY GROUP, a research organization focused on combination lipid therapy for type 2 diabetes mellitus, and includes a network of researchers, studies, and medical journals such as The Lancet and Circulation. These entities are interconnected through research collaborations, publications, and shared focus on cardiovascular and metabolic health. The community's work contributes significantly to the understanding and treatment of cardiovascular diseases and diabetes.\",\n    \"rating\": 7.5,\n    \"rating_explanation\": \"The impact severity rating is high due to the community's significant contributions to medical research and potential to influence clinical practices and patient outcomes globally.\",\n    \"findings\": [\n        {\n            \"summary\": \"ACCORD STUDY GROUP's pivotal role in diabetes research\",\n            \"explanation\": \"The ACCORD STUDY GROUP is a key entity in this community, focusing on the effects of combination lipid therapy in individuals with type 2 diabetes mellitus. Their research has been published in prestigious journals like the New England Journal of Medicine, highlighting its importance and credibility. This group's work is crucial for advancing the management of diabetes and its cardiovascular complications. [Data: Entities (3137), Relationships (2669, 2673)]\"\n        },\n        {\n            \"summary\": \"The Lancet's influence in disseminating cardiovascular research\",\n            \"explanation\": \"The Lancet serves as a critical platform for publishing high-impact cardiovascular and metabolic research, including studies from the ACCORD STUDY GROUP and INSIGHT study. Its role in disseminating research findings amplifies the community's impact on medical science and clinical practice. [Data: Entities (1338), Relationships (1127, 2683, 4692)]\"\n        },\n        {\n            \"summary\": \"Collaborative research on hypertension and cardiovascular outcomes\",\n            \"explanation\": \"Researchers like BROWN MJ and PALMER CR have contributed to the INSIGHT study, focusing on hypertension treatment. Their work, published in The Lancet, underscores the community's collaborative efforts to address cardiovascular diseases. [Data: Entities (1334, 1335), Relationships (1124, 1125)]\"\n        },\n        {\n            \"summary\": \"Significance of the LIFE study in hypertension research\",\n            \"explanation\": \"The LIFE study, with contributions from researchers like VIITASALO M and OIKARINEN L, explores the prognostic value of electrocardiographic strain patterns in hypertensive patients. Published in Circulation, this study adds valuable insights into cardiovascular risk assessment. [Data: Entities (1317, 1349, 1348), Relationships (1105, 1108, 4665)]\"\n        },\n        {\n            \"summary\": \"Advancements in cholesterol management and cardiovascular disease\",\n            \"explanation\": \"The Cholesterol Treatment Trialists Collaborators and researchers like SABATINE M S and GIUGLIANO R P have advanced the understanding of cholesterol-lowering therapies and their impact on cardiovascular disease. Their publications in The Lancet and NEJM highlight the community's role in shaping treatment strategies. [Data: Entities (3104, 3153, 3148), Relationships (2682, 2676)]\"\n        }\n    ]\n}", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752169011, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 668, "prompt_tokens": 5848, "total_tokens": 6516, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1536}, "prompt_cache_hit_tokens": 1536, "prompt_cache_miss_tokens": 4312}}, "input": {"messages": [{"content": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            },\n            {\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }\n        ]\n    }\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nLimit the total report length to 2000 words.\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        },\n        {\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        },\n        {\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        },\n        {\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }\n    ]\n}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n3137,ACCORD STUDY GROUP,\"The **ACCORD STUDY GROUP** is a research organization focused on investigating the effects of combination lipid therapy in individuals with **type 2 diabetes mellitus**. The group has conducted studies to evaluate the efficacy and potential benefits of this therapeutic approach in managing the condition. Both descriptions emphasize the group's primary focus on combination lipid therapy as a treatment strategy for type 2 diabetes, indicating a consistent research direction. The ACCORD STUDY GROUP's work contributes to the broader understanding of metabolic disease management and aims to improve clinical outcomes for patients with diabetes.\",4\r\n1337,INTERNATIONAL NIFEDIPINE GITS STUDY: INTERVENTION AS A GOAL IN HYPERTENSION TREATMENT (INSIGHT),\"A study comparing long-acting calcium-channel blocker or diuretic treatment in hypertension\"\"\",4\r\n1338,LANCET,\"**The Lancet** is a weekly peer-reviewed general medical journal and a leading publication in the field of medicine. It covers a broad range of medical research, including clinical trials, meta-analyses, and studies on cardiovascular treatments, cholesterol management, hypertension, and acute stroke assessment.  \n\nThe journal has published significant studies such as the **INSIGHT study**, as well as phase 3 trials on microsomal triglyceride transfer protein inhibitors. In 2007, it featured research comparing **MRI and CT in acute stroke assessment**, contributing to advancements in diagnostic imaging. Additionally, **The Lancet** is known for disseminating high-impact research on **hypertension** and **cardiovascular outcomes**, reinforcing its role as a key resource for evidence-based medicine.  \n\nBy publishing rigorous peer-reviewed studies, **The Lancet** remains a trusted source for clinicians, researchers, and policymakers seeking the latest developments in medical science. Its comprehensive coverage spans from specialized clinical trials to broader meta-analyses, ensuring its relevance across multiple medical disciplines.\",8\r\n1323,CIRCULATION,\"**CIRCULATION** is a peer-reviewed medical journal published by the American Heart Association (AHA), dedicated to advancing research in cardiovascular health and disease. The journal serves as a leading platform for high-quality studies on cardiovascular diseases, treatments, and related metabolic conditions. Notably, in 2007, *Circulation* published a study examining the components of metabolic syndrome, contributing to the understanding of its impact on cardiovascular health. Additionally, the journal has featured significant clinical trial findings, such as the results of the LIFE study, which explored cardiovascular outcomes in specific patient populations.  \n\nAs a prominent publication in its field, *Circulation* focuses on disseminating cutting-edge research, including clinical, translational, and basic science studies, to improve the prevention, diagnosis, and management of cardiovascular conditions. Its broad scope encompasses topics ranging from atherosclerosis and heart failure to innovative therapeutic approaches. By publishing influential studies and fostering scientific discourse, *Circulation* plays a key role in shaping cardiovascular medicine and informing clinical practice worldwide.\",5\r\n3164,NEJM,,6\r\n3104,CHOLESTEROL TREATMENT TRIALISTS COLLABORATORS,\"The **Cholesterol Treatment Trialists Collaborators** (CTTC) is a collaborative research group focused on analyzing data from clinical trials related to cholesterol treatment. The group conducts meta-analyses to evaluate the efficacy of cholesterol-lowering therapies, particularly in populations with specific health conditions such as diabetes. By synthesizing data from multiple trials, the CTTC provides evidence-based insights into the benefits and potential impacts of cholesterol-lowering interventions. Their work contributes to a deeper understanding of how these therapies affect patient outcomes, helping to inform clinical guidelines and treatment strategies. The CTTC operates as a collective effort, pooling expertise and data to produce comprehensive, large-scale analyses in the field of cardiovascular and metabolic health.\",2\r\n4498,INSIGHT,,2\r\n1317,LOSARTAN INTERVENTION FOR END-POINT REDUCTION IN HYPERTENSION STUDY (LIFE),\"The **LOSARTAN INTERVENTION FOR END-POINT REDUCTION IN HYPERTENSION STUDY (LIFE)** is a clinical study focused on evaluating the prognostic significance of changes in the electrocardiographic (ECG) strain pattern during antihypertensive treatment. The study investigates whether alterations in this ECG marker—a known indicator of left ventricular hypertrophy and adverse cardiovascular outcomes—can predict patient prognosis when treated with antihypertensive therapies. By analyzing these changes, the LIFE study aims to provide insights into the relationship between ECG strain patterns, blood pressure management, and long-term cardiovascular risk.  \n\nThe descriptions consistently emphasize the study's primary objective: assessing the prognostic value of ECG strain pattern modifications in the context of antihypertensive treatment. There are no contradictions in the provided data, as all descriptions align in their focus on the ECG strain pattern as a key metric for evaluating treatment outcomes. The LIFE study contributes to understanding how electrocardiographic markers may serve as valuable tools for risk stratification and therapeutic monitoring in hypertensive patients.  \n\nIn summary, the LIFE study is a well-defined investigation into the clinical relevance of ECG strain pattern changes during antihypertensive therapy, with implications for improving cardiovascular risk assessment and management.\",4\r\n1334,BROWN MJ,\"**BROWN MJ** is a researcher affiliated with the **INSIGHT hypertension study**, also referred to as the **International Nifedipine GITS study**. This study focuses on investigating hypertension (high blood pressure) and the effects of nifedipine, a calcium channel blocker, in its gastrointestinal therapeutic system (GITS) formulation. BROWN MJ's involvement highlights their expertise in cardiovascular research, particularly in clinical trials related to antihypertensive treatments. The study is significant for its contributions to understanding the efficacy and safety of nifedipine GITS in managing hypertension.  \n\nThe descriptions consistently emphasize BROWN MJ's role in this research, with slight variations in naming—whether as the **\"\"INSIGHT study\"\"** or the **\"\"International Nifedipine GITS study\"\"**—both referring to the same initiative. There are no contradictions in the provided information, only complementary details reinforcing their association with this hypertension-focused clinical trial.  \n\nIn summary, BROWN MJ is a key researcher in the **INSIGHT study (International Nifedipine GITS study)**, contributing to advancements in hypertension treatment through their work on nifedipine GITS. Their affiliation underscores their specialization in cardiovascular pharmacology and large-scale clinical research.\",5\r\n3153,SABATINE M S,Sabatine M S is a researcher involved in studies on evolocumab and clinical outcomes in patients with cardiovascular disease,2\r\n3155,FELLSTR?M B C,Fellstr?m B C is a researcher involved in studies on rosuvastatin and cardiovascular events in patients undergoing hemodialysis,2\r\n1349,VIITASALO M,\"**VIITASALO M** is a researcher who has been involved in studies examining the prognostic value of electrocardiographic strain patterns, particularly in the context of antihypertensive treatment. Their work is notably associated with the LIFE (Losartan Intervention For Endpoint Reduction in Hypertension) study, which investigated the significance of electrocardiographic strain patterns as potential prognostic markers in hypertensive patients. The research contributes to understanding how these patterns may predict cardiovascular outcomes during antihypertensive therapy. The descriptions align in highlighting VIITASALO M's focus on electrocardiographic strain patterns and their clinical implications, particularly within the framework of the LIFE study. No contradictions are present in the provided descriptions.  \n\n(Word count: 100)\",3\r\n1335,PALMER CR,\"**PALMER CR** is a researcher known for their involvement in two significant medical studies: the **INSIGHT study** and the **International Nifedipine GITS study**. The INSIGHT study (International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment) was a large-scale clinical trial investigating the efficacy of nifedipine, a calcium channel blocker, in managing hypertension. PALMER CR contributed to this research, which aimed to evaluate the drug's effectiveness in achieving blood pressure control.  \n\nAdditionally, PALMER CR participated in the **International Nifedipine GITS study**, further emphasizing their expertise in cardiovascular research, particularly in the use of nifedipine's gastrointestinal therapeutic system (GITS) formulation. This study likely explored the drug's pharmacokinetics, safety, and therapeutic outcomes in a global context.  \n\nPALMER CR's dual involvement in these studies highlights their focus on hypertension treatment and pharmacological interventions, contributing valuable insights to the field of cardiovascular medicine. Their work underscores the importance of large-scale, international collaborations in advancing clinical understanding and patient care.\",3\r\n3150,O'DONOGHUE M L,O'Donoghue M L is a researcher involved in studies on long-term evolocumab in patients with established atherosclerotic cardiovascular disease,2\r\n3152,FITZGERALD K,Fitzgerald K is a researcher involved in developing a highly durable RNAi therapeutic inhibitor of PCSK9,1\r\n1365,OKIN PM,,4\r\n1348,OIKARINEN L,\"**OIKARINEN L** is a researcher who has contributed to studies examining the prognostic significance of electrocardiographic strain patterns, particularly in the context of antihypertensive treatment. Their work is notably associated with the LIFE (Losartan Intervention For Endpoint Reduction in Hypertension) study, which investigated the relationship between electrocardiographic strain patterns and cardiovascular outcomes in hypertensive patients. The research underscores the clinical relevance of these patterns as potential markers for risk stratification during antihypertensive therapy. By consolidating findings from these studies, OIKARINEN L's work highlights the importance of electrocardiographic monitoring in managing hypertension and predicting cardiovascular events.\",3\r\n4488,CASTAIGNE A,Researcher involved in the International Nifedipine GITS study,2\r\n2323,LLOYD-JONES DM,Lead author of a study on longitudinal changes in metabolic syndrome components published in Circulation,1\r\n3131,YOKOYAMA M,Yokoyama M is a researcher involved in coronary events and hypercholesterolemia studies>,4\r\n3132,ORIGASA H,Origasa H is a researcher involved in coronary events and hypercholesterolemia studies>,2\r\n3133,MATSUZAKI M,Matsuzaki M is a researcher involved in coronary events and hypercholesterolemia studies>,2\r\n3134,KEECH A,Keech A is a researcher involved in fenofibrate therapy and cardiovascular events studies>,4\r\n3135,SIMES R J,Simes R J is a researcher involved in fenofibrate therapy and cardiovascular events studies>,2\r\n3136,BARTER P,Barter P is a researcher involved in fenofibrate therapy and cardiovascular events studies>,2\r\n1336,CASTAGNE A,\"Researcher involved in the INSIGHT study\"\"\",1\r\n3145,JELIS,A randomized study on eicosapentaenoic acid effects in hypercholesterolemic patients>,1\r\n3146,FIELD STUDY,A randomized controlled trial of fenofibrate therapy in type 2 diabetes patients>,1\r\n3147,ACCORD TRIAL,A clinical trial investigating combination lipid therapy in type 2 diabetes>,1\r\n3148,GIUGLIANO R P,Giugliano R P is a researcher involved in multiple studies on cholesterol management and cardiovascular disease,3\r\n4808,CUCHEL M,\"Researcher involved in a phase 3 study of a microsomal triglyceride transfer protein inhibitor\"\"\",3\r\n4809,MEAGHER EA,\"Researcher involved in a phase 3 study of a microsomal triglyceride transfer protein inhibitor\"\"\",2\r\n4810,DU TOIT THERON H,\"Researcher involved in a phase 3 study of a microsomal triglyceride transfer protein inhibitor\"\"\",2\r\n3138,CANNON C P,\"**Cannon C P** is a researcher specializing in cardiovascular studies, with a particular focus on the effects of ezetimibe when added to statin therapy in patients recovering from acute coronary syndromes. His work contributes to advancing the understanding of treatment strategies for cardiovascular diseases, particularly in post-acute coronary syndrome care. By investigating the combined use of ezetimibe and statins, Cannon C P aims to improve therapeutic outcomes for patients with heightened cardiovascular risk. His research underscores the importance of optimizing lipid-lowering therapies to enhance patient recovery and long-term health.\",3\r\n3139,BLAZING M A,Blazing M A is a researcher involved in cardiovascular studies>,1\r\n3154,WANNER C,Wanner C is a researcher involved in studies on atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis,2\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,combined_degree\r\n2669,ACCORD STUDY GROUP,N ENGL J MED,Published ACCORD trial results in NEJM,13\r\n1127,INTERNATIONAL NIFEDIPINE GITS STUDY: INTERVENTION AS A GOAL IN HYPERTENSION TREATMENT (INSIGHT),LANCET,The INSIGHT study results were published in the Lancet journal,12\r\n1109,CIRCULATION,FRAMINGHAM HEART STUDY,The Framingham Heart Study results were published in the Circulation journal,11\r\n1595,LANCET,WARACH S,Warach S co-authored a study published in Lancet,11\r\n2673,ACCORD STUDY GROUP,NEJM,The Accord Study Group published their findings on combination lipid therapy in the New England Journal of Medicine,10\r\n2683,CHOLESTEROL TREATMENT TRIALISTS COLLABORATORS,LANCET,The Cholesterol Treatment Trialists published meta-analyses in The Lancet,10\r\n4692,LANCET,INSIGHT,INSIGHT study results published in The Lancet,10\r\n1105,LOSARTAN INTERVENTION FOR END-POINT REDUCTION IN HYPERTENSION STUDY (LIFE),CIRCULATION,The LIFE study results were published in the Circulation journal,9\r\n1124,BROWN MJ,INTERNATIONAL NIFEDIPINE GITS STUDY: INTERVENTION AS A GOAL IN HYPERTENSION TREATMENT (INSIGHT),Brown MJ was involved in the INSIGHT study,9\r\n2682,SABATINE M S,NEJM,Sabatine M S published research on evolocumab in the New England Journal of Medicine,8\r\n2686,FELLSTR?M B C,NEJM,Fellstr?m B C published research on rosuvastatin in the New England Journal of Medicine,8\r\n1108,LOSARTAN INTERVENTION FOR END-POINT REDUCTION IN HYPERTENSION STUDY (LIFE),VIITASALO M,Viitasalo M was involved in the LIFE study,7\r\n1125,PALMER CR,INTERNATIONAL NIFEDIPINE GITS STUDY: INTERVENTION AS A GOAL IN HYPERTENSION TREATMENT (INSIGHT),Palmer CR was involved in the INSIGHT study,7\r\n2679,O'DONOGHUE M L,CIRCULATION,O'Donoghue M L published research on evolocumab in Circulation journal,7\r\n2681,FITZGERALD K,NEJM,Fitzgerald K published research on PCSK9 inhibitors in the New England Journal of Medicine,7\r\n4662,OKIN PM,OIKARINEN L,Co-authors on a study about the prognostic value of electrocardiographic strain patterns during antihypertensive treatment,7\r\n4682,BROWN MJ,CASTAIGNE A,Co-authors on the International Nifedipine GITS study,7\r\n2013,LLOYD-JONES DM,CIRCULATION,LLOYD-JONES DM published a study in Circulation,6\r\n2659,YOKOYAMA M,ORIGASA H,Collaborated on coronary events and hypercholesterolemia research,6\r\n2660,YOKOYAMA M,MATSUZAKI M,Collaborated on coronary events and hypercholesterolemia research,6\r\n2664,KEECH A,SIMES R J,Collaborated on fenofibrate therapy and cardiovascular events research,6\r\n2665,KEECH A,BARTER P,Collaborated on fenofibrate therapy and cardiovascular events research,6\r\n4665,OIKARINEN L,VIITASALO M,Co-authors on a study about the prognostic value of electrocardiographic strain patterns during antihypertensive treatment,6\r\n1126,CASTAGNE A,INTERNATIONAL NIFEDIPINE GITS STUDY: INTERVENTION AS A GOAL IN HYPERTENSION TREATMENT (INSIGHT),Castagne A was involved in the INSIGHT study,5\r\n2662,YOKOYAMA M,JELIS,Led the JELIS randomized study,5\r\n2667,KEECH A,FIELD STUDY,Led the FIELD randomized controlled trial,5\r\n2670,ACCORD STUDY GROUP,ACCORD TRIAL,Conducted the ACCORD clinical trial,5\r\n2676,GIUGLIANO R P,SABATINE M S,Sabatine M S and Giugliano R P collaborated on research about evolocumab and clinical outcomes in patients with cardiovascular disease,5\r\n5052,CUCHEL M,MEAGHER EA,Both researchers were involved in the same phase 3 study of a microsomal triglyceride transfer protein inhibitor,5\r\n5053,CUCHEL M,DU TOIT THERON H,Both researchers were involved in the same phase 3 study of a microsomal triglyceride transfer protein inhibitor,5\r\n2663,ORIGASA H,MATSUZAKI M,Collaborated on coronary events and hypercholesterolemia research,4\r\n2668,SIMES R J,BARTER P,Collaborated on fenofibrate therapy and cardiovascular events research,4\r\n2671,CANNON C P,BLAZING M A,Collaborated on cardiovascular research,4\r\n2684,WANNER C,FELLSTR?M B C,Wanner C and Fellstr?m B C both conducted research on statin therapy in patients undergoing hemodialysis,4\r\n5055,MEAGHER EA,DU TOIT THERON H,Both researchers were involved in the same phase 3 study of a microsomal triglyceride transfer protein inhibitor,4\r\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            },\n            {\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }\n        ]\n    }\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nLimit the total report length to 2000 words.\n\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0, "response_format": {"type": "json_object"}}}, "key": "chat_create_community_report_40f4876608c8b2b2e3f971e98777e29498da21c8164eded51ee6731d3ccb5d63_v2"}